Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies.
In the present in vivo study the uptake kinetics of radioiodinated albumin were determined in normal organs, and tumours of rats using sequential scintigraphy. Rat serum (RSA) was radioiodinated either directly at a tyrosine residue (d-RSA), or indirectly at a residualizing marker tagged to the albumin (rm-RSA). These labelling procedures did not alter the kinetics of labelled albumin, as shown by blood disappearance curves. Directly labelled albumin was shown to have tumour uptake. Residualizing markers like tyramine-cellobiose (TCB), tyramine-deoxysorbitol (TDS) and aminonaphthaltyrimide-deoxysorbitol (ANTDS) are metabolically inert. After the intracellular degradation of the albumin carrier the TCB-, TDS- and ATNDS-residues accumulate in the lysosomes, particularly those of tumour cells. It was able to be demonstrated that residualizing-marker tagged albumin-bound radioactivity was five times higher after 72 h than the tumour radioactivity after use of directly labelled RSA. These data found support when whole-body retention of directly labelled RSA, and residualizing marker-RSAs, were determined. After 72 h, 60% of 131I bound to RSA directly had been excreted, compared to only 25% of the activity attached indirectly to RSA with a residualizing marker. Whole-body autoradiography of rats injected with directly labelled RSA, or residualizing marker-RSA, support these results. Most of the radioactivity of directly labelled RSA was excreted within 24 h, whereas labelled residualizing marker-RSAs were also stored in tumour and liver tissue. ANTDS bound to RSA allows fluorescence microscopy. Cryosections of tumours from rats preinjected 10 min and 24 h with ANTDS-RSA before dissection, demonstrated that the fluorescence is localized on and in tumour cells. This indicates that cellular uptake of the marker takes place. Fluorescence was not observed in muscle tissue. This appears to suggest that the albumin uptake is greater in tumours than in normal tissue, and that it is metabolized in the tumour cells.
Schilling
U
U
Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Friedrich
E A
EA
Sinn
H
H
Schrenk
H H
HH
Clorius
J H
JH
Maier-Borst
W
W
D000818:Animals; D002475:Cellobiose / Q000493:pharmacokinetics*; D004337:Drug Carriers; D005260:Female; D007457:Iodine Radioisotopes; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000378:metabolism*; D011877:Radionuclide Imaging; D051381:Rats; D011919:Rats, Inbred Strains; D012709:Serum Albumin / Q000493:pharmacokinetics*; D013012:Sorbitol / Q000493:pharmacokinetics* / Q000031:analogs & derivatives; D014018:Tissue Distribution; D014439:Tyramine / Q000493:pharmacokinetics* / Q000031:analogs & derivatives
D004337:Drug Carriers; D007457:Iodine Radioisotopes; D012709:Serum Albumin; C038394:tyramine-cellobiose adduct; C076628:tyramine-deoxysorbitol; D002475:Cellobiose; D013012:Sorbitol; D014439:Tyramine